Melanoma

1. Front Matter

   Pages i-xvi

   PDF

2. Perspective on the Clinical Disease

   1. Front Matter

      Pages 1-1

      PDF

   2. Management of Primary Malignant Melanoma

      • Philip L. Bailin, Jon S. Meine, Christine Poblete-Lopez

      Pages 3-38

   3. A Pathologist’s Perspective on Prognostic Features of Malignant Melanoma

      • Ralph J. Tuthill

      Pages 39-72

   4. Clinical Prognostic Factors and Staging

      • Hamed Daw, Thomas Olencki

      Pages 73-92

3. Biological and Targeted Therapeutics

   1. Front Matter

      Pages 93-93

      PDF

   2. Principles of Antitumor Immunity and Tumor-Mediated Immunosuppression

      • Peter A. Cohen, Suyu Shu, James H. Finke

      Pages 95-139

   3. Immunotherapy of Advanced Melanoma Directed at Specific Antigens

      • Stanley P. L. Leong, Suyu Shu

      Pages 141-156

   4. Melanoma Antigens

      • Paul B. Chapman, Jedd D. Wolchok

      Pages 157-182

   5. Interleukin-2

      • James W. Mier, Michael B. Atkins

      Pages 183-219

   6. Interleukin-12

      • Ronald M. Bukowski, Charles Tannenbaum

      Pages 221-234

   7. Interferons

      • Ernest C. Borden

      Pages 235-258

   8. Biochemotherapy of Melanoma

      • Lawrence E. Flaherty, Philip Agop Philip

      Pages 259-285

   9. Signal Transduction Abnormalities as Therapeutic Targets

      • Ruth Halaban, Maria C. von Willebrand

      Pages 287-323

   10. Tumor Angiogenesis

       • Bela Anand-Apte, Paul L. Fox

       Pages 325-360

   11. Antiangiogenic Therapy for Melanoma

       • Vann P. Parker

       Pages 361-377

4. Back Matter

   Pages 379-389

   PDF

Strategies of treatment involving therapeutic proteins, irnrnune immune cells, or cel­ lular protein targets are those of greatest potential for further reducing mortality from melanoma. Therapeutic proteins or cells may inhibit melanoma cell growth either by augmentation of immune cell function or by inhibition of angiogenesis. Cytokines and melanoma antigens may be used either in vivo as a vaccine to stimulate irnrnune immune cell cell function or ex vivo to stimulate or proliferate cells for infusion. Alternatively, alteration in melanoma cell growth can occur through inhibition of protein signal transduction pathways within melanoma cells or in the endothelial cells constituting the necessary angiogenic support for tumor growth. The great promise of these therapies and their cellular targets constitutes the basis for Melanoma: Biologically Targeted Therapeutics. THE CLINlCAL PROBLEM More than four million people will be diagnosed with melanoma in the first decade of the 21st century. Half of those who will die will be individuals who would otherwise have had a life expectancy of another 25 years or more. These individuals will die of systemic systernic metastases, which are present at the time of primary surgery. Despite use of sunscreens, incidence continues to increase in developed countries worldwide. To reduce mortality, there must continue to be a focus on prevention and earlier detection through public education. Early interventions are always preferable to treatment of disseminated metastatic disease.

• Staging
• angiogenesis
• metastatic disease
• surgery
• tumor growth

"Incredible detail to immunologic mechanisms is the strong point of the book. The bibliography at the end of each chapter is exhaustive, sometimes citing over 300 references.The pharmacokinetics of cytokines are meticulously discussed and diagrammed. Tables summarizing the results of clinical trials to date are peppered throughout the book. The authors are careful not to draw conclusions that do not have support from prospective randomized clinical trials. It is an excellent source to become familiar with current research and experimental protocols for advanced melanoma. Researchers and directors of melanoma clinics at tertiary care facilities will want to have this book as a resource."-Weighted Numerical Score: 100 - 5 Stars!-Doody's Health S ciences Book Review Journal

• Center for Cancer Drug Discovery and Development, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, USA

  Ernest C. Borden

Policies and ethics